Communicable Diseases

Overview

Communicable diseases remain one of the most significant threats to health, economic stability, and development across Africa. Despite global progress, infectious diseases continue to disproportionately affect vulnerable populations, particularly children, pregnant women, and underserved communities.

At Victoria Biomedical Research Institute (VIBRI), we work with donors, governments, and global health partners to generate rigorous scientific evidence that accelerates the development of vaccines, therapeutics, diagnostics, and prevention strategies. Donor investment enables us to translate research into real-world solutions that save lives and strengthen health systems.

Priority Therapuetic Areas

01

Malaria

Malaria remains a leading cause of preventable illness and death in sub-Saharan Africa. With donor support, VIBRI evaluates next-generation malaria vaccines, antimalarial drug regimens, and prevention strategies aligned with regional and global elimination goals. These studies directly inform national policy and large-scale malaria control programs.
02

HIV/AIDS

HIV continues to exert long-term pressure on individuals, families, and healthcare systems. VIBRI’s donor-funded clinical trials and observational studies contribute to improved antiretroviral therapies, prevention tools, and vaccine development, supporting reduced transmission and improved quality of life.
03

Tuberculosis (TB)

Tuberculosis, particularly in HIV co-infected populations, requires sustained innovation. VIBRI conducts research into novel diagnostics and treatment approaches that shorten treatment duration, improve adherence, and reduce community transmission.
04

Pneumonia and Diarrheal Diseases

Pneumonia and diarrheal illnesses remain among the leading causes of child mortality. Our research evaluates vaccine effectiveness, treatment protocols, and community-based interventions that improve child survival and strengthen primary healthcare delivery.
05

Emerging and Re-Emerging Infectious Diseases

Emerging health threats such as Ebola, COVID-19, and Rift Valley Fever demand rapid, credible research responses. With donor investment, VIBRI conducts vaccine safety, immunogenicity, and effectiveness studies that inform national preparedness and global health security.
01

Malaria

Malaria remains a leading cause of preventable illness and death in sub-Saharan Africa. With donor support, VIBRI evaluates next-generation malaria vaccines, antimalarial drug regimens, and prevention strategies aligned with regional and global elimination goals. These studies directly inform national policy and large-scale malaria control programs.
02

HIV/AIDS

HIV continues to exert long-term pressure on individuals, families, and healthcare systems. VIBRI’s donor-funded clinical trials and observational studies contribute to improved antiretroviral therapies, prevention tools, and vaccine development, supporting reduced transmission and improved quality of life.
03

Tuberculosis (TB)

Tuberculosis, particularly in HIV co-infected populations, requires sustained innovation. VIBRI conducts research into novel diagnostics and treatment approaches that shorten treatment duration, improve adherence, and reduce community transmission.
04

Pneumonia and Diarrheal Diseases

Pneumonia and diarrheal illnesses remain among the leading causes of child mortality. Our research evaluates vaccine effectiveness, treatment protocols, and community-based interventions that improve child survival and strengthen primary healthcare delivery.
05

Emerging and Re-Emerging Infectious Diseases

Emerging health threats such as Ebola, COVID-19, and Rift Valley Fever demand rapid, credible research responses. With donor investment, VIBRI conducts vaccine safety, immunogenicity, and effectiveness studies that inform national preparedness and global health security.

Our Research Model

  • Donor-funded Phase I–IV clinical trials

  • Vaccine and drug safety monitoring

  • Rapid-response epidemic research

  • Strong ethical oversight and community engagement

  • Strategic partnerships with regional and global institutions

Impact for Donors

Investment in communicable disease research delivers measurable and lasting impact:

  • Evidence that informs national and global health policy

  • Accelerated access to life-saving vaccines and treatments

  • Strengthened African research capacity

  • Reduced disease burden and improved population health outcomes

Partner With Us

Support VIBRI’s mission to advance solutions for Africa’s most urgent infectious disease challenges.

Request Feasibility Study
Therapeutic Focus